New lupus drug afimetoran enters Mid-Stage trial
Disease control
Ongoing
This phase 2 trial tests whether the drug afimetoran can safely control active systemic lupus erythematosus (SLE) better than a placebo. About 268 participants with lupus will receive either afimetoran or a placebo for 48 weeks, with an extension period allowing placebo users to …
Phase 2 • Sponsor: Beeline Medicines Corporation • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC